- TheStreet.com•18 days ago
Amicus Therapeutics (FOLD) CEO John Crowley joined Thursday morning's 'Squawk Box' on CNBC to discuss the future of the company and new medications in the pipeline.
- GlobeNewswire•19 days agoUPDATE -- New England Journal of Medicine Publishes Pivotal Phase 3 FACETS Study of Migalastat for Patients with Fabry Disease
CRANBURY, N.J., Aug. 10, 2016-- Amicus Therapeutics, a biotechnology company at the forefront of rare and orphan diseases, today announced that data from the pivotal Phase 3 Study 011 evaluating the efficacy ...
AMICUS THERA (AM6.BE)
Berlin - Berlin Delayed Price. Currency in EUR
As of 2:07 AM EDT. Market open.
|Bid||0.00 x 32100|
|Ask||0.00 x 30900|
|Day's Range||5.96 - 5.96|
|52wk Range||4.47 - 16.20|
|1y Target Est||N/A|
|P/E Ratio (ttm)||N/A|
|Avg Vol (3m)||81|
|Dividend & Yield||N/A (N/A)|